ClinicalTrials.gg
Status unknownNCT02906878PLATCATUpdated Sep 20, 2016

Platelet Kinetics After Platelet Transfusion for the Placement of a Central Venous Catheter

An observational study in Thrombopenia and Central Venous Catheter Placement, sponsored by University Hospital, Angers. Status unknown at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-09-20.

Sponsored by University Hospital, Angers · Observational

The sponsor has not verified this record recently (last verified Sep 2016), so the status shown — last known as Recruiting — may be out of date.
Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
30
Ages
18 Years and older
Sex
All
01

Study summary

PLATCAT study's purpose is to evaluate platelet kinetics after platelet transfusion

02

Conditions studied

  • Thrombopenia
  • Central Venous Catheter Placement

Browse trials for

Keywords

  • Intensive Care
  • Haematology
  • Platelets prophylactic transfusion
03

In context

Thrombocytopenia

703 studies on the registry are indexed under Thrombocytopenia; 150 are open to participants now.

This study's planned enrollment of 30 is below the median of 120 across 186 observational studies indexed under Thrombocytopenia.

Browse Thrombocytopenia studies →

Lead sponsor

University Hospital, Angers is the lead sponsor of 477 studies on the registry; 119 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Haematology patients who needs a central venous catheter and with a non-auto immune thrombopenia

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Admission en haematology unit
  • Need for a central venous catheter
  • Thrombopenia \< 50 G/L

Exclusion criteria

Exclusion Criteria:

  • Patient protected by law
  • Pregnant or breastfeeding women
  • Peripheral thrombopenia
  • Patient admitted in Intensive Care Unit
05

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
30 participants (estimated)
Patient registry
No

Interventions

  • ProcedurePlatelets transfusion

    Prophylactic platelet transfusion in thrombocytopenic patients for the placement of a central venous catheter

06

What researchers measure

Primary outcomes

  1. 72 hours thrombocythemia kinetics after a platelet transfusion

    Blood drawing a H-1:00, H+0:10, H+1:00, H+4:00, H+24h00, H+72:00 Evaluation of platelets count on sodium citrate tube.

    Time frame: 72 hours post transfusion

Secondary outcomes

  1. Transfusion Safety - assessed by Troubles during process

    Troubles during process (pneumothorax, laying failure, hematoma) Hematoma at H+24:00 Immunisation anti HLA,HPA

    Time frame: One day after transfusion

  2. Transfusion Efficacy

    Number of blood or platelets transfusion

    Time frame: One month after transfusion

  3. Description of patients treatment

    Type of received chemotherapy

    Time frame: One week before and one month after transfusion

07

Study locations

1 of 1 sites recruiting
  • University Hospital
    Angers, 49933, France
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2016, a primary completion of Jul 2017 and a completion of Jul 2017. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 5, 2016
First posted
Sep 20, 2016
Start
Jun 2016
Primary completionEst.
Jul 2017
CompletionEst.
Jul 2017
Last update
Sep 20, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 20, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02906878
Responsible party
Sponsor
First posted
Sep 20, 2016
Start date
Jun 2016
Primary completion
Jul 2017 (estimated)
Completion
Jul 2017 (estimated)
Last update
Sep 20, 2016

Study contacts

Nicolas LEROLLE, MD PhD
Contact
NiLerolle@chu-angers.fr
+33241353478
Aline SCHMIDT, MD
Contact
alschmidt@chu-angers.fr
Nicolas LEROLLE, MD PhD
principal investigator · University Hospital, Angers

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Sep 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion